Kura Oncology Inc. (NASDAQ:KURA) fell 3.1% on Monday . The company traded as low as $4.89 and last traded at $5.00, with a volume of 189,643 shares changing hands. The stock had previously closed at $5.16.

A number of brokerages recently weighed in on KURA. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a research report on Sunday. Zacks Investment Research upgraded shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price for the company in a research report on Wednesday, July 13th.

The company has a 50-day moving average of $3.88 and a 200-day moving average of $3.64. The stock’s market capitalization is $94.78 million.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by $0.02. On average, equities analysts forecast that Kura Oncology Inc. will post ($1.72) earnings per share for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.